The manufacturer of Lokelma is AstraZeneca [1][2].
Who else makes Lokelma?
Lokelma is exclusively manufactured by AstraZeneca.
What is Lokelma used for?
Lokelma, also known by its generic name, sodium zirconium cyclosilicate, is a medication used to treat hyperkalemia, a condition characterized by elevated potassium levels in the blood [1][3]. It works by binding to potassium in the gastrointestinal tract, thereby reducing the amount of potassium absorbed into the bloodstream [3].
How does Lokelma work and what are its benefits?
Lokelma functions as a selective potassium binder [3]. By irreversibly binding potassium in the colon, it facilitates the excretion of excess potassium through feces [3]. This mechanism helps to lower serum potassium levels and maintain them within a normal range. Clinical studies have shown Lokelma's effectiveness in reducing and maintaining serum potassium levels in adult patients with hyperkalemia [1].
When does Lokelma's patent expire?
Information regarding the specific patent expiration dates for Lokelma is available through resources like DrugPatentWatch.com [4]. These dates are crucial for understanding when generic versions of the drug might become available.
What are the risks associated with Lokelma?
The primary risks associated with Lokelma are related to its mechanism of action, which involves binding to potassium. This can potentially lead to hypokalemia (low potassium levels) if not monitored properly. Other potential side effects include gastrointestinal issues such as constipation, diarrhea, and nausea. Patients should consult their healthcare provider for a comprehensive understanding of potential risks and side effects.
Can Lokelma be used by children?
Lokelma is indicated for the treatment of hyperkalemia in adult patients [1][3]. Its use in pediatric populations has not been as extensively studied, and prescribers should consider the available data and individual patient needs.
How does Lokelma compare to other hyperkalemia treatments?
Other treatments for hyperkalemia include dietary restrictions, loop diuretics, and other potassium binders like patiromer. Lokelma offers a distinct binding mechanism and is known for its rapid onset of action and sustained potassium-lowering effects [3]. Comparisons between these medications often focus on their efficacy, speed of action, tolerability, and potential side effects.
What is the typical dosage for Lokelma?
The typical starting dose for Lokelma in adults is 10 grams once daily, with the potential to adjust the dose based on serum potassium levels and patient response. Dosing regimens can vary, and patients should adhere to their healthcare provider's instructions [1][3].
Where can I find more information on Lokelma's intellectual property and market exclusivity?
Detailed information on Lokelma's patent status, including expiration dates and any related litigation, can be found on specialized databases such as DrugPatentWatch.com [4]. This site tracks pharmaceutical patents, providing insights into market exclusivity and the potential for generic competition.
What are the clinical trial results for Lokelma?
Clinical trials for Lokelma have demonstrated its ability to effectively reduce and maintain serum potassium levels in adult patients with hyperkalemia. Studies have shown rapid reductions in potassium within the first 48 hours of treatment and sustained control over longer periods [1][3].
What is the cost of Lokelma?
The cost of Lokelma can vary depending on insurance coverage, pharmacy pricing, and geographical location. Pricing information is typically available through pharmacies and patient assistance programs offered by the manufacturer.
---
Sources:
[1] AstraZeneca. LOKELMA® (sodium zirconium cyclosilicate). https://www.astrazeneca.com/our-medicines/lokelma.html
[2] Lokelma (sodium zirconium cyclosilicate). U.S. Food & Drug Administration. https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/lokelma-sodium-zirconium-cyclosilicate
[3] Sodium Zirconium Cyclosilicate. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/diseases-conditions/hyperkalemia/sodium-zirconium-cyclosilicate
[4] DrugPatentWatch. https://drugpatentwatch.com/